Biomarkers of Pediatric Pnuemonia

Student Researcher:
Jack Underschultz

Supervisor / Principle Investigator:
Dr. Michael Hawkes

Additional Authors:
Michael Hawkes
Bob Opoka
Andrea Conroy
Sophie Namasopo
Jeremy Soo
Ravi Bhargava

MD Class of 2021

ABSTRACT

Introduction: Pneumonia is the leading cause of childhood infectious death globally. Chest x-ray (CXR) is commonly used as a diagnostic tool, but is not available in many resource-limited areas of the world. We hypothesized that serum biomarkers of inflammation, endothelial activation, and lung injury would be associated with CXR consolidation and could be used as a point-of-care diagnostic test to replace the CXR.

Methods: We conducted a cross-sectional study of 108 Ugandan children hospitalized with clinical pneumonia. All children received a CXR. Enzyme-linked immunosorbent assays were performed to measure serum host response biomarkers: C-reactive protein (CRP), Chitinase 3-like 1 (CHI3L1), Lipocalin-2 (LCN2), Tie-2, Intercellular adhesion molecule-1 (ICAM1), endoglin, Tissue Inhibitor of Metalloprotease-1 (TIMP1), and surfactant protein-D (SP-D).

Results: A total of 108 children were included and categorized by CXR findings as primary end-point pneumonia (n=24), other infiltrates (n=49), or normal CXR (n=35). Clinical variables such as respiratory rate and chest indrawing were not predictive of CXR consolidation. Compared to children with normal x-ray, children with end-point pneumonia had significantly higher levels of CRP, CHI3L1, LCN2, and SP-D. CRP had the best discriminatory power (AUROC 0.73) with a sensitivity of 71% and a specificity of 79%. Compared to children with other infiltrates, children with end-point pneumonia had elevated CRP, CHI3L1, LCN2, ICAM1, and TIMP1. CRP had the best discriminatory power (AUROC 0.75) with a sensitivity of 63% and a specificity of 89%. Biomarkers did not differ statistically between children with other infiltrates and those with normal chest x-rays.

Conclusions: In Ugandan children with clinical pneumonia, host biomarkers distinguished between end-point pneumonia, other infiltrates, and normal CXR; however, the sensitivity and specificity of any individual biomarker may not be sufficient to have clinical utility. Further work exploring the enhanced test performance characteristics of combinations of biomarkers is underway.

 
 

Next